Achillion Pharmaceuticals

About Achillion

Leadership

Joseph Truitt

President and Chief Executive Officer

Paul Firuta

Executive Vice President, Chief Operating Officer

Steven Zelenkofske, D.O.

Chief Medical Officer

Anthony S. Gibney

Chief Business Officer

Mingjun Huang

Senior Vice President, Head of Research

Mary Kay Fenton

Executive Vice President and Chief Financial Officer

Martha Manning, Esq

Executive Vice President, General Counsel and Secretary

Michael Banks, PhD

Senior Vice President, Pharmaceutical Sciences

Ky Nam-Wortman

Senior Vice President, Head of Human Resources

Brian Di Donato

Vice President, Investor Relations & Corporate Communications

President and Chief Executive Officer

Mr. Truitt was appointed Achillion’s Chief Executive Officer in May 2018. Mr. Truitt joined Achillion in January 2009 from Viropharma, Inc. following its acquisition of Lev Pharmaceuticals. At Lev, Mr. Truitt was most recently Vice President of Business Development and Product Strategy and led the build out of the commercial team and infrastructure in preparation for product launch. Mr. Truitt joined Lev from Johnson & Johnson, where he was Vice President of Sales and Operations and directed commercial operations and had P&L responsibility for sales, operations and national accounts at the company’s OraPharma subsidiary. Mr. Truitt holds a BS degree in Marketing from LaSalle University, Philadelphia, and an MBA degree from St. Joseph’s University, Philadelphia.

Back to Top ↑
Executive Vice President, Chief Operating Officer

Mr. Firuta is responsibile for leading commercial strategy and operations, market access, pharmaceutical sciences & manufacturing, project management and patient advocacy. Mr. Firuta was formerly Chief Commercial Officer of from uniQure N.V. (NASDAQ: QURE) where he held the position of. Prior to uniQure, he was President of U.S. Commercial Operations at NPS Pharmaceuticals where he led the development and execution of the GATTEX sales and marketing plan as well as the commercial launch of NAPTARA. Over the course of his career, Mr. Firuta has held various leadership roles at biopharmaceutical companies including: Vice President and General Manager, Americas at ViroPharma, Inc. leading the U.S. commercial operations for CINRYZE and VANCOCIN, representing over $400 million in U.S. revenue. Additionally, he was Vice President, Managed Markets at LEV Pharmaceuticals and Executive Director National Accounts at OraPharma. Mr. Firuta holds a Master of Business Administration from St. Joseph’s University in Philadelphia and a Bachelor of Science degree from King’s College, Wilkes-Barre, Pennsylvania.

Back to Top ↑
Chief Medical Officer

Dr. Zelenkofske brings more than 20 years of industry development experience, most recently as Chief Medical Officer of UniQure, a clinical stage gene therapy company, and previously as Chief Medical Officer of Regado Biosciences. He has also held leadership positions at Astra-Zeneca, Sanofi-Aventis, Boston Scientific and Novartis. Dr. Zelenkofske completed his residency training at Philadelphia College of Osteopathic Medicine, followed by fellowships in cardiology and electrophysiology at Graduate Hospital, Philadelphia, and St. Luke’s Hospital, New York, respectively. He is a graduate of Emory University, where he also earned a Master of Science degree in immunopharmacology. He earned his Doctor of Osteopathy from Philadelphia College of Oseopathic Medicine. He is a fellow of the American College of Cardiology, the American College of Chest Physicians, and the American College of Osteopathic Internists.

Back to Top ↑
Chief Business Officer

Prior to joining Achillion, Mr. Gibney was an investment banker for almost 25 years, completing over 150 merger and acquisition and financing transactions as a lead advisor to US and EU-based life science clients. Most recently, he was a Managing Director and Co-Head of the Biotechnology Investment Banking Team at Leerink Partners. Prior to that, Tony worked in the Healthcare Group at Merrill Lynch, Inc., where he ultimately led the East Coast Biotechnology origination effort as a Managing Director. Tony began his professional career as an analyst and associate in the Healthcare Investment Banking Group at Lehman Brothers Inc. Tony holds a Bachelor of Arts degree in History and Economics from Yale University.

Back to Top ↑
Senior Vice President, Head of Research

Dr. Huang joined Achillion in 2001 and currently serves as Senior Vice President and Head of Research. Dr. Huang began her tenure at Achillion as Director of Biology and has advanced through her outstanding contributions to the Company’s discovery efforts and innovations in building the portfolio. She is a pioneer in the discovery and development of the first oral factor D inhibitor, ACH-4471, as well as the next-generation compounds. Dr. Huang received her medical training at Shanghai Medical School, Fudan University, her Ph.D. at the University of New Mexico, and her postdoctoral training at the National Institutes of Health. She was a research fellow at National Cancer Institute and also head of antiviral research at Southern Research Institute prior to joining Achillion.

Back to Top ↑
Executive Vice President and Chief Financial Officer

Ms. Fenton, a certified public accountant, has led Achillion’s financial function since October 2000, and is responsible for financial strategy development and capital formation, financial reporting and compliance, treasury and tax functions, as well as operating functions including risk management, legal compliance, facilities management, purchasing, and information technology. From 1991 to 2000, Ms. Fenton held various positions within the Technology Industry Group at PricewaterhouseCoopers LLC, most recently as Senior Manager responsible for the life sciences practice in Connecticut. Prior to 1991, Ms. Fenton was an economic development associate in the nonprofit sector. Ms. Fenton holds an MBA in Finance from the Graduate School of Business at the University of Connecticut and an AB in Economics from the College of the Holy Cross.

Back to Top ↑
Executive Vice President, General Counsel and Secretary

Martha E. Manning, Esq. joined Achillion in February 2016 as General Counsel. Previously, she was General Counsel of iCeutica Inc., a drug development company from 2013 to 2016. She served as Chief Legal Officer of OraPharma, Inc., a J&J spinout company, from 2011 to 2012 when the Company was acquired by Valeant. She joined OraPharma from Sandoz Inc., the generic pharmaceutical division of Novartis, where she served as Vice President and General Counsel from 2008 to 2011. Prior to Sandoz, she served as Senior Vice President, General Counsel and Secretary for Adolor Corporation, a publicly traded biopharmaceutical company from 2002 to 2008. Martha began her legal career with the law firm of Morgan, Lewis & Bockius. She received her J.D. from the University of Pennsylvania School of Law and her Bachelor of Business Administration from the University of Massachusetts.

Back to Top ↑
Senior Vice President, Pharmaceutical Sciences

Dr. Banks joined Achillion in 2013, leading all Chemical Manufacturing & Control (CMC) activities and later taking on additional responsibility to include quality assurance and compliance. Dr. Banks has over 30 years of experience in pharmaceutical research and development. His career has included 27 years with Pfizer in the UK and USA encompassing various functions and increasing levels of responsibility in CMC. Prior to Pfizer, Dr. Banks was head of formulation development within the International Development Centre of Abbott Laboratories, UK. He has a wealth of experience progressing compounds from early development through to successful, global regulatory approvals and commercialization.

He is a pharmacist and graduated from Leicester School of Pharmacy with a BSc (Hons) Pharmacy degree and a PhD in Pharmaceutical Technology. He later earned a MBA with distinction from University of Kent in the UK.

Back to Top ↑
Senior Vice President, Head of Human Resources

Ms. Nam-Wortman joined Achillion in October 2014 as the Vice President of Human Resources. She brings over 23 years of experience in human resources and strategic change management from Zoetis, Pfizer, Merck, IBM, and Delta Consulting Group. Prior to joining Achillion, she was the Vice President of Talent & Organization Capability for Zoetis (formerly Pfizer Animal Health), Vice President & HR Lead for Pfizer, and has held positions of increasing responsibility while at Pfizer and Merck. Ms. Nam-Wortman has 14 years of experience in the consulting industry focused on strategic and organization change management from Delta Consulting Group and IBM. She received her bachelors in marketing from New York University Stern School of Business and MS in human resources management / organization development from the New School of Social Research.

Back to Top ↑
Vice President, Investor Relations & Corporate Communications

Brian is an experienced capital markets banker, investor and fund manager, having previously held positions as Managing Director and co-portfolio manager at Sorin Capital Management and President and Chief Investment Officer of Capmark Investments. He previously worked in investment banking capital markets at both Morgan Stanley and UBS Securities. Brian holds Bachelor of Science degrees in Biology from Penn State University and in Mechanical Engineering from Villanova University, as well as a Masters of Business Administration from New York University’s Stern School of Business. Prior to business school Brian was an aerospace engineering officer in the US Navy.

Back to Top ↑